A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations Rochester, MN The purpose of this study is to evaluate and compare 2 doses …

2025年1月10日 · The biotech company Ocugen has launched a Phase 3 clinical trial for its gene-agnostic, modifier gene therapy under development for people with retinitis pigmentosa (RP). The trial will enroll approximately 150 participants at 15 sites in the US.

2025年2月7日 · Retinitis pigmentosa is an inherited disease that slowly damages the retina, leading to vision loss. UCSF is studying the PRPF31 mutation to learn about the disease's progression. Another trial is investigating if oral N-acetylcysteine can affect retinitis pigmentosa.

2024年10月20日 · Luxturna (voretigene neparvovec) is the first FDA-approved gene therapy for retinitis pigmentosa. It works by replacing a faulty gene with a healthy one. But it only works in people who have a specific gene mutation, RPE65, which represents 0.3 to 1 percent of all retinitis pigmentosa cases.

2024年4月3日 · Wilmer Eye Institute has been awarded more than $20M from the @NatEyeInstitute. Researchers will investigate a possible first-of-its-kind treatment for retinitis pigmentosa, a genetic eye condition causing blindness. ›

2025年2月10日 · This is a Phase 3 study to Assess the Efficacy, Safety and Tolerability of OCU400 in patients with retinitis pigmentosa (RP) associated with RHO mutations and patients with any other RP associated mutation with a clinical phenotype of RP.

2025年2月10日 · This is a Phase 3 study to Assess the Efficacy, Safety and Tolerability of OCU400 in patients with retinitis pigmentosa (RP) associated with RHO mutations and patients with any other RP associated mutation with a clinical phenotype of RP.

2025年1月31日 · In a phase I clinical trial in patients with RP, oral administration of NAC for 6 months was well-tolerated and resulted in a small but statistically significant improvement in visual acuity and light sensitivity in the retina.

16 小时之前 · OCU400’s phase 3 liMeliGhT clinical trial ((ClinicalTrials.gov identifier: NCT06388200) is currently in progress, ... Therapeutics N. Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa. Nanoscope Therapeutics. March 26, 2024.

2025年1月3日 · In this Phase 1 open-labeled prospective study, one eye of each participant with vision loss from retinitis pigmentosa will be administered intravitreal injection of autologous CD34+ stem cells harvested from bone marrow.